PD-1 blockade in advanced NSCLC: A focus on pembrolizumab

Cancer Treatment Reviews

Volumn 62, Issue , 2018, Pages 39-49

  Peters, Solange ^a   Kerr, Keith M ^b   Stahel, Rolf ^c  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anti PD 1 antibody; Non small cell lung cancer; PD L1; Pembrolizumab

Indexed keywords

AFATINIB; ATEZOLIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PROGRAMMED DEATH 1 RECEPTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADVANCED CANCER; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CELL VIABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPEAN MEDICINES AGENCY; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; METASTASIS POTENTIAL; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; LUNG TUMOR; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85034629880     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2017.10.002     Document Type: Review

References (91)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:5 (2015), E359–E386.
2. Arnold, M., Pandeya, N., Byrnes, G., Renehan, A.G., Stevens, G.A., Ezzati, M., et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 16:1 (2015), 36–46.
3. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:2 (2002), 92–98.
4. NCCN clinical practice guidelines in oncology: Non-small cell lung cancer version 5. 2017.
5. Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M.G., et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27:suppl 5 (2016), v1–27.
6. Gerber, D.E., Schiller, J.H., Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. J Clin Oncol 31:8 (2013), 1009–1020.
7. Hirsh, V., Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. Curr Oncol 17:2 (2010), 13–23.
8. Alimta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2016.
9. Taxotere [package insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2010.
10. Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O'Rourke, M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:10 (2000), 2095–2103.
11. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., de Marinis, F., von Pawel, J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:9 (2004), 1589–1597.
12. Haura, E.B., Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control 8:4 (2001), 326–336.
13. Desai, A., Menon, S.P., Dy, G.K., Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. Cancer Biol Med 13:1 (2016), 77–86.
14. Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:1 (2006), 2–16.
15. Fazio, N., Buzzoni, R., Baudin, E., Antonuzzo, L., Hubner, R., Lahner, H., et al. A phase II study of BEZ235 in patients with everoliums-resistant, advanced pancreatic neuroendocrine tumours. Anticancer Res 36:2 (2016), 713–719.
16. Steuer, C.E., Ramalingam, S.S., ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer 120:16 (2014), 2392–2402.
17. Wu, J., Savooji, J., Liu, D., Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol, 9, 2016, 19.
18. Blackhall, F.H., Peters, S., Bubendorf, L., Dafni, U., Kerr, K.M., Hager, H., et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol 32:25 (2014), 2780–2787.
19. Wang, S., Cang, S., Liu, D., Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol, 9, 2016, 34.
20. Janne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., et al. AZD9291 in EGFR inhibitor–resistant non–small-cell lung cancer. N Engl J Med 372:18 (2015), 1689–1699.
21. Yu, H.A., Arcila, M.E., Rekhtman, N., Sima, C.S., Zakowski, M.F., Pao, W., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:8 (2013), 2240–2247.
22. Xalkori [summary of product characteristics]. Sandwick, UK: Pfizer Limited; 2016.
23. Xalkori [package insert]. New York, NY: Pfizer inc; 2017.
24. Alecensa [package insert]. South San Francisco, CA: Genentech, Inc.; 2016.
25. Zykadia [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016.
26. Shaw, A.T., Kim, D.W., Mehra, R., Tan, D.S., Felip, E., Chow, L.Q., et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 370:13 (2014), 1189–1197.
27. Ou, S.H., Ahn, J.S., De, P.L., Govindan, R., Yang, J.C., Hughes, B., et al. Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase II global study. J Clin Oncol 34:7 (2016), 661–668.
28. Caccese, M., Ferrara, R., Pilotto, S., Carbognin, L., Grizzi, G., Calio, A., et al. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opin Pharmacother 17 (2016), 2253–2266.
29. Peters, S., Camidge, D.R., Shaw, A.T., Gadgeel, S., Ahn, J.S., Kim, D.W., et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:9 (2017), 829–838.
30. Rothschild, S.I., Targeted therapies in non-small cell lung cancer—beyond EGFR and ALK. Cancers (Basel) 7:2 (2015), 930–949.
31. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 372:21 (2015), 2018–2028.
32. Scarpace, S.L., Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context, 4, 2015, 212289.
33. Armand, P., Immune checkpoint blockade in hematologic malignancies. Blood 125:22 (2015), 3393–3400.
34. Bustamante Alvarez, J.G., Gonzalez-Cao, M., Karachaliou, N., Santarpia, M., Viteri, S., Teixido, C., et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 12:3 (2015), 209–222.
35. Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:10030 (2016), 1837–1846.
36. Dang, T.O., Ogunniyi, A., Barbee, M.S., Drilon, A., Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. Expert Rev Anticancer Ther 16:1 (2016), 13–20.
37. Tecentriq [package insert]. South San Francicso, CA: Genentech, Inc.; 2017.
38. Opdivo [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2017.
39. European Medicines Agency. Opdivo nivolumab. Committee for Medicinal Products for Human Use; 2016.
40. Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2017.
41. Keytruda [summary of product characteristics]. Hertfordshire, United Kingdom; Merck Sharp & Dohme, Limited; 2017.
42. Sharpe, Merck., Corp, Dohme., European Commission approves MSD's anti-PD-1 therapy, Keytruda (pembrolizumab), for both first-line and previously treated patients with advanced melanoma. 2015, Merck Sharpe & Dohme, Kenilworth, NJ.
43. US Food and Drug Administration. FDA approves Keytruda for advanced non-small cell lung cancer [approval letter]; 2014.
44. Sul, J., Blumenthal, G.M., Jiang, X., He, K., Keegan, P., Pazdur, R., FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death ligand 1. Oncologist 21:5 (2016), 643–650.
45. Merck & Co., Inc. KEYTRUDA® (pembrolizumab) approved as first anti-PD-1 therapy in Japan for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 [press release]. Kenilworth, NJ: Merck & Co., Inc; 2016.
46. Gandhi, L., Balmanoukian, A., Hui, R., Hamid, O., Rizvi, N.A., Leighl, N., et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer: antitumor activity and association with tumor PD-L1 expression. Cancer Res, 74(19 suppl), 2014 Abstract CT105.
47. Hui, R., Gandhi, L., Costa, E.C., Felip, E., Ahn, M.-J., Eder, J.P., et al. Long-term overall survival for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). Presented at: ASCO Annual Meeting, June 3–7, 2016, Chicago, IL. Abstract 9026. J Clin Oncol, 34(suppl), 2016, 9026.
48. Khoja, L., Butler, M.O., Kang, S.P., Ebbinghaus, S., Joshua, A.M., Pembrolizumab. J Immunother Cancer, 3, 2015, 36.
49. Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Pérez-Gracia, J.L., Han, J.Y., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:10027 (2016), 1540–1550.
50. Brahmer, J.R., Kim, E.S., Zhang, J., Smith, M.M., Rangwala, R.A., O'Brien, M.E.R., KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1). J Clin Oncol, 33(suppl), 2015 Abstract TPS8103.
51. Reck, M., Rodriguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fulop, A., et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375:19 (2016), 1823–1833.
52. Business Wire. Merck's KEYTRUDA® (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer [press release]. Published June 16, 2016. http://www.businesswire.com/news/home/20160616005393/en/Merck%E2%80%99s-KEYTRUDA%C2%AE%C2%A0-pembrolizumab-Demonstrates-Superior-Progression-Free-Survival.
53. Langer, C.J., Gadgeel, S.M., Borghaei, H., Papadimitrakopoulou, V.A., Patnaik, A., Powell, S.F., et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 17:11 (2016), 1497–1508.
54. Rizvi, N., Barlesi, F., Brahmer, J., Felip, E., Forde, P., Garrasino, M., et al. Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC. J Immunother Cancer, 3(suppl 2), 2015, P171.
55. Antonia, S., Goldberg, S.B., Balmanoukian, A., Chaft, J.E., Sanborn, R.E., Gupta, A., et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17:3 (2016), 299–308.
56. Cho, B.C., Kim, J.H., Villegas, A., Frusch, N., Murakami, S., Shi, K., et al. Phase 3, double-blind, placebo-controlled study of MEDI4736 after chemoradiation in stage III, locally advanced, unresectable NSCLC (PACIFIC). J Thorac Oncol, 10(9 suppl 2), 2015, S668.
57. Planchard, D., Yokoi, T., McCleod, M.J., Fischer, J.R., Kim, Y.C., Ballas, M., et al. A phase III study of curvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung Cancer 17:3 (2016), 232–236.
58. Verschraegen, C.F., Chen, F., Spigel, D.R., Iannotti, N., McClay, E.F., Redfern, C.H., et al. Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN solid tumor phase 1b trial: safety, clinical activity, and PD-L1 expression. J Clin Oncol, 34(suppl), 2016 Abstract 9036.
59. Reck, M., DeGreen, H.P., Rose, A.L., Pavlakis, N., Derjcke, S.M., Radic, J., et al. Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial. J Clin Oncol, 34(suppl), 2016 Abstract TPS9105.
60. Lin, Z., Xu, Y., Zhang, Y., He, Q., Zhang, J., He, J., et al. The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures. Oncotarget 7:12 (2016), 15033–15046.
61. Passiglia, F., Bronte, G., Bazan, V., Natoli, C., Rizzo, S., Galvano, A., et al. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget 7:15 (2016), 19738–19747.
62. Dako North America, Inc. PD-L1 IHC 22C3 pharmDx. Dako North America Inc: Carpinteria, CA; 2015.
63. Dako Agilent Pathology Solutions. PD-L1 IHC 28–8 pharmDx: Interpretation Manual—Non-squamous non-small cell lung cancer (ROW Version); 2016.
64. Ventana Medical Systems Inc. VENTANA PD-L1 (SP263) Assay; 2017.
65. Roche Group Media Relations. Roche announces FDA approval for VENTANA PD-L1 (SP142) Assay to support immunotherapy treatment decisions in lung cancer [press release]. Published October 27; 2016. < http://www.prnewswire.com/news-releases/roche-announces-fda-approval-for-ventana-pd-l1-sp142-assay-to-support-immunotherapy-treatment-decisions-in-lung-cancer-300352191.html>.
66. Hirsch FR, Averbuch S, Emami T, Walker J, Williams A, Stanforth D, et al. The Blueprint Project: harmonizing companion diagnostics across a class of targeted therapies. New Orleans, LA; 2016.
67. Averbuch S, Emancipator K, McCaffery I, McEilhinny A, Stanforth D, Walker J, et al. A blueprint proposal for companion diagnostic comparability. < https://www.fda.gov/downloads/medicaldevices/newsevents/workshopsconferences/ucm439440.pdf> [accessed July 20, 2017].
68. Kerr, K.M., Bubendorf, L., Edelman, M.J., Marchetti, A., Mok, T., Novello, S., et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol 25:9 (2014), 1681–1690.
69. Dolled-Filhart, M., Locke, D., Murphy, T., Lynch, F., Yearley, J.H., Frisman, D., et al. Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue. Arch Pathol Lab Med 140:11 (2016), 1259–1266.
70. Phillips, T., Simmons, P., Inzunza, H.D., Cogswell, J., Novotny, J. Jr., Taylor, C., et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 23:8 (2015), 541–549.
71. Liu, D., Wang, S., Bindeman, W., Clinical applications of PD-L1 bioassays for cancer immunotherapy. J Hematol Oncol, 10, 2017, 110.
72. Rebelatto, M.C., Midha, A., Mistry, A., Sabalos, C., Schechter, N., Li, X., et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol, 11(1), 2016, 95.
73. Roach, C., Zhang, N., Corigliano, E., Jansson, M., Toland, G., Ponto, G., et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 24:6 (2016), 392–397.
74. Dolled-Filhart, M., Roach, C., Toland, G., Stanforth, D., Jansson, M., Lubiniecki, G.M., et al. Development of a companion diagnostic for pembrolizumab in non–small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med, 2016 [Epub ahead of print].
75. Garon EB, Herbst RS, Kim D-W, Felip E, Perez-Gracia JL, Han J-Y, et al. Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: results from KEYNOTE-010. Presented at: ASCO Annual Meeting, June 3–7, 2016, Chicago, IL. Abstract 9024.
76. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:17 (2015), 1627–1639.
77. Sorensen, S.F., Zhou, W., Dolled-Filhart, M., Georgsen, J.B., Wang, Z., Emancipator, K., et al. PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol 9:1 (2016), 64–69.
78. Karim, S., Leighl, N., Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. Future Oncol 12:1 (2016), 9–23.
79. Brahmer, J., Reckamp, K.L., Baas, P., Crino, L., Eberhardt, W.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:2 (2015), 123–135.
80. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:10066 (2017), 255–265.
81. Socinski, M., Horn, L., Steins, M., Ciuleanu, T.E., Ready, N., Nair, R.G., et al. A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC. Ann Oncol, 27(suppl 6), 2016 [Abstract LBA7-PR].
82. Ilie, M., Hofman, V., Dietel, M., Soria, J.C., Hofman, P., Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 468:5 (2016), 511–525.
83. Buchbinder, E.I., Desai, A., CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:1 (2016), 98–106.
84. Patnaik, A., Kang, S.P., Rasco, D., Papadopoulos, K.P., Elassaiss-Schaap, J., Beeram, M., et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21:19 (2015), 4286–4293.
85. Seiwert, T.Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J.P., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17:7 (2016), 956–965.
86. Herbst, R.S., Baas, P., Perez-Garcia, J.L., Felip, E., Kim, D.W., Han, J.Y., et al. Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. J Clin Oncol, 34(suppl), 2016 Abstract 3030.
87. Ilie, M., Long-Mira, E., Bence, C., Butori, C., Lassalle, S., Bouhlel, L., et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27:1 (2016), 147–153.
88. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:6230 (2015), 124–128.
89. Peters S, Creelan B, Hellman MD, Socinski MA, Reck M, Bhagavatheeswaran P, et al. Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate 026. Presented at: AACR Annual Meeting 2017, Washington, DC, April 1–5, 2017.
90. Besse, B., Johnson, M.L., Janne, P.A., Garissino, M., Eberhardt, W.E.E., Peters, S., et al. Phase II single arm trial (BIRCH) of atezolizumab as first line or subsequent therapy for locally advanced or metastatic PD-L1 selected NSCLC. Eur J Cancer 51:suppl 3 (2015), S717–718.
91. Barlesi, F., Von Pawel, J., Kowalski, D., Leach, J., Gandara, D., Chen, D.S., et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol, 27(Suppl. 6), 2016 [Abstract LBA44_PR].